Marion Wright
Psychiatry · Kinston, NCNPI 1699986364
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $50,210 of the $55,268 with a category attached, or 90.8%. AbbVie accounts for 97.2% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2021 at $22,539 and has fallen 98.7% since, to $294 in 2025. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 154 payments — averaging $358.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$54K
- Teva Pharmaceuticals USA, Inc.$256
- Otsuka America Pharmaceutical, Inc.$246
- Lundbeck LLC$242
- Tris Pharma Inc$199
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$77
- plus $551 from 20 others
What the payments were for
- Speaking & faculty fees$50,21091%
- Travel & lodging$2,9065%
- Food & beverage$2,1524%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$55,268 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abilify MaintenaAripiprazole | 11 | $28,348 |
| VraylarCariprazine Hcl | 15 | $21,818 |
| AuvelityDextromethorphan Hbr/Bupropion | 18 | $19,508 |
| Lurasidone Hcl | 36 | $7,432 |
| TrintellixVortioxetine Hydrobromide | 15 | $7,078 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 89 | $3,438 |
| Clorazepate Dipotassium | 12 | $2,538 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 26 | $1,538 |
| Clonazepam | 119 | $1,297 |
| Alprazolam | 190 | $1,283 |
| Duloxetine Hcl | 55 | $1,038 |
| Atomoxetine Hcl | 18 | $1,025 |
| Quetiapine Fumarate | 58 | $1,019 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 63 | $867 |
| Zolpidem Tartrate | 96 | $847 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $246 | $28,34811 claims |
| AbbVieVraylar | $53,697 | $21,81815 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $35 | $7,07815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Kinston
- Craig ChepkeHuntersville$4.1M
- Mark ReynoldsDurham$3.2M
- James BarkerHickory$2.1M
- Brian FarahWinston Salem$605K
- Krishna TalluriMorrisville$591K
- Ramesh GihwalaGastonia$545K
- Keshavpal ReddyGreensboro$480K
- Robert MilletRaleigh$476K
- Steven SzaboDurham$360K
- David JoyeAlbemarle$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.